Cargando…

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration

Thrombocytopenia is a frequent complication in chronic lymphocytic leukemia (CLL). Differentiating autoimmune thrombocytopenia from thrombocytopenia due to bone marrow infiltration is necessary for appropriate treatment, but sometimes difficult. Here we report a 60-year-old male patient with CLL who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oyama, Takashi, Yasunaga, Megumi, Jona, Masahiro, Nishikawa, Masako, Yatomi, Yutaka, Honda, Akira, Maki, Hiroaki, Morita, Ken, Masamoto, Yosuke, Kurokawa, Mineo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JSLRT 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628828/ https://www.ncbi.nlm.nih.gov/pubmed/37635085 http://dx.doi.org/10.3960/jslrt.23023

Ejemplares similares

Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation
por: Yoshida, Mina, et al.
Publicado: (2023)

Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

Development of Epstein–Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma
por: Yoshida, Mina, et al.
Publicado: (2022)

Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review
por: Obo, Takafumi, et al.
Publicado: (2023)

Bing-Neel Syndrome Successfully Treated with Tirabrutinib
por: Oyama, Takashi, et al.
Publicado: (2022)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

Reduced bendamustine for elderly patients with follicular lymphoma
por: Masamoto, Yosuke, et al.
Publicado: (2021)

Involvement of Band3 in the efflux of sphingosine 1-phosphate from erythrocytes
por: Kurano, Makoto, et al.
Publicado: (2017)

Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma
por: Fukui, Yuta, et al.
Publicado: (2022)

Aortitis Associated with Prophylactic Short-acting Granulocyte Colony-stimulating Factor Administration: A Case Report and Review of the Literature
por: Masuda, Yasutaka, et al.
Publicado: (2023)

Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation
por: Mizuno, Hideaki, et al.
Publicado: (2021)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

Analysis of urinary sphingolipids using liquid chromatography‐tandem mass spectrometry in diabetic nephropathy
por: Morita, Yoshifumi, et al.
Publicado: (2019)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
por: Ghia, Paolo, et al.
Publicado: (2022)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
por: Vreman, Rick A., et al.
Publicado: (2019)

Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
por: Izutsu, Koji, et al.
Publicado: (2021)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
por: Masamoto, Yosuke, et al.
Publicado: (2022)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
por: Strati, Paolo, et al.
Publicado: (2022)

P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
por: Skarbnik, Alan, et al.
Publicado: (2023)

Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseases
por: Nishikawa, Masako, et al.
Publicado: (2019)

Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromosome 16 rearrangements
por: Fukushima, Hidehito, et al.
Publicado: (2023)

Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review
por: Kurihara, Yuya, et al.
Publicado: (2021)

P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
por: Phillips, Tycel, et al.
Publicado: (2023)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M(27) in human plasma and application to a human pharmacokinetic study
por: Valluri, Venkat Rao, et al.
Publicado: (2022)

Dihydro-sphingosine 1-phosphate interacts with carrier proteins in a manner distinct from that of sphingosine 1-phosphate
por: Mishima, Yuko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hkodtcg91bns8sgoopi98oal4t